NCT06161025
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 23 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 68 words
- Trial sites expanded: 164 → 167 locations
- Secondary endpoints: details revised at 5 of 21 entries
- Collaborators: details revised at 1 of 1 entry
- Minor Trial sites expanded: 152 → 164 locationsv23
- Minor Trial sites expanded: 146 → 152 locationsv22
- Minor Trial sites expanded: 129 → 146 locationsv21
- Minor Trial sites expanded: 120 → 129 locationsv20
Show 17 earlier versionsHide 17 earlier versions
Notable Eligibility criteria shortened, about 374 wordsv19 Show 7 more changesShow less
- Primary endpoints: 3 to 2
- Enrollment target: 710 to 860
- Primary completion date: Dec 31, 2027 to Feb 29, 2028
- Study completion date: Dec 31, 2029 to Apr 30, 2030
- Interventions: Gemcitabine (Drug), PLD (Drug), Paclitaxel (Drug), R-DXd (Drug), Topotecan (Drug) to PLD (Drug), Paclitaxel (Drug), R-DXd (Drug), Topotecan (Drug)
- Secondary endpoints: 16 to 21
- Site details revised at 47 of 120 sites
- Minor Study sites: 116 to 120v18
- Minor Study sites: 115 to 116v17
- Minor Study sites: 108 to 115v16
Notable Trial status: Active, Not Recruiting to Recruitingv15 Show 5 more changesShow less
- Eligibility criteria shortened, about 9 words
- Primary endpoints revised (3)
- Enrollment target: 650 to 710
- Study sites: 82 to 108
- Secondary endpoints revised (16)
- Minor Study sites: 81 to 82v13
- Minor Study sites: 78 to 81v12
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites revised (78)
- Minor Study sites: 54 to 78v10
- Minor Study sites: 40 to 54v9
- Minor Study sites: 15 to 40v8
- Minor Study sites: 13 to 15v7
- Minor Study sites: 3 to 13v6
- Minor Study title shortened, about 1 wordv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Feb 29, 2024 to Feb 27, 2024
- Notable Eligibility criteria expanded, about 1,081 wordsv3
- Minor Secondary endpoints revised (16)v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).
Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).
Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).
Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.
Drugs: R-DXd, Paclitaxel, Topotecan, PLD
Sites
167 sites in 19 countries
United States 45, Japan 14, China 13, France 12, Italy 11, Spain 11, South Korea 9, Taiwan 6, Canada 5, Czechia 5, Germany 5, Turkey (Türkiye) 5, United Kingdom 5, Australia 4, Brazil 4, Greece 4, Poland 4, Portugal 4, Finland 1